Medical Appointment & Lab Review – Comprehensive Study Notes

Blood Work & Laboratory Findings

  • Complete Blood Count (CBC)

    • White blood cells, red blood cells, and platelet count all within normal ranges ⇒ no evidence of anemia or acute infection.

  • Electrolytes & Serum Proteins

    • All major ions (Na⁺, K⁺, Cl⁻, HCO₃⁻) and total protein/albumin reported as normal.
    • Implication: adequate overall metabolic and nutritional status; no acute dehydration or protein‐losing condition detected.

  • Renal Panel / Kidney Markers

    • Estimated Glomerular Filtration Rate (eGFR): 53\,\text{mL}\,\text{min}^{-1}\,(>60\,\text{normal},>90\,\text{ideal}).
    • Signifies mild–moderate renal insufficiency (Stage 3a CKD).
    • Likely secondary to previous urinary obstruction from prostate enlargement → back pressure on kidneys.
    • Prognosis: may recover if obstruction fully relieved + aggressive hydration.

  • Lipid Profile

    • Low-Density Lipoprotein (LDL-C): 53 mg dL−153\,\text{mg}\,\text{dL}^{-1}.
    • Considered excellent (goal <100; <70 for very high risk).
    • Not taking any statin/other lipid-lowering therapy → suggests favorable baseline metabolism or lifestyle.

  • Iron Studies

    • “Low end of normal” but still normal for serum iron, ferritin, TIBC, TSAT.
    • Indicates no iron-deficiency despite chronic disease background.

  • Average Blood Glucose / HbA1c

    • Reported value: 5.0%5.0\% (interpreted as HbA1c).
    • Falls in euglycemic range (<5.7 %).
    • No diabetes or impaired glucose tolerance.

  • Vitamin D

    • “Looks good.” Implies serum 25-OH‐D in sufficient zone (≥30 ng/mL).

Current Medication List & Assessment

  • Existing regimen judged “pretty decent.” (Individual drugs not enumerated in clip.)
  • No active lipid-lowering, antidiabetics, or NSAIDs were identified.
  • Concern: Avoid nephrotoxic/renally-cleared agents given eGFR 53.

Pain & Symptom Management Discussion

  • Patient experiencing:

    • Significant intestinal discomfort.
    • Generalized body aches (chronic pain component).

  • Treatments considered

    1. Gabapentin
    • Mechanism: α₂δ Ca²⁺–channel modulation → dampens neuropathic pain signaling.
    • Advantages: non-opioid, non-constipating, renal dose‐adjustable.
    • Previously used “a long time ago”; unclear past efficacy.
    • Common SE: mild sedation, dizziness (usually transient).
    1. Duloxetine (Cymbalta) – mistakenly pronounced “teloxetine.”
    • SNRI class; addresses pain + mood (dual benefit for cancer patients).
    • Often synergistic with gabapentin.
    • Added constipation-neutral profile → good vs. opioids.

  • Plan: Prescriptions for gabapentin 300 mg (exact schedule TBD) + possibly duloxetine; pharmacy to be CVS 5408 Ignacio Ave., Concord, CA.

Kidney-Protection Counseling

  • Hydration Strategy: “Hydrate aggressively” → ≥2–3 L water/day (unless contraindicated).
  • Medication Avoidance: No NSAIDs (ibuprofen, naproxen, meloxicam) to prevent further GFR decline.
  • Reversibility Outlook: Renal function may rebound if post-obstructive damage resolves.

Oncology / Prostate-Cancer Care Pathway

  • Follow-up physicians:
    • Currently with Dr. Costa (Enloe, Chico).
    • Transitioning to UC Davis oncology/urology team.
  • Bone scan status: “I think there was—yeah.” ⇒ Unclear if metastatic spread confirmed; pending clarification.

Administrative & Next Steps

  • Lab order for future blood work will be printed; can be picked up at Dr. Hart’s Yuba City office closer to next visit.
  • Follow-up appointment: set ≈ 2 weeks to evaluate:
    • Pain control effectiveness.
    • Tolerability of new medications.
    • Re-check renal panel + any oncology updates.
  • Caregiver (Todd) will pick up medications once called in.

Practical / Ethical Considerations & Connections

  • Patient-centered pain control: Preference for regimens minimizing constipation and sedation given quality-of-life focus in oncology.
  • Interdisciplinary coordination: Primary care ↔ oncology ↔ pharmacy; emphasizes need for clear communication when multiple specialists involved.
  • Chronic Kidney Disease (CKD) Monitoring: Early identification (eGFR 53) allows lifestyle + pharmacologic interventions to slow progression.
  • Psychosocial aspect: Using duloxetine addresses potential depression/anxiety linked with cancer pain.

Key Take-Home Formulae & Targets

  • eGFR normal > 6060; ideal > 9090 – current 5353 → Stage 3a CKD.
  • LDL target < 100 mg dL−1100\,\text{mg}\,\text{dL}^{-1} (high risk < 7070); current 5353 → optimal.
  • HbA1c normal < 5.7%5.7\%; current 5.0%5.0\% → normoglycemia.

Follow-up Checklist

  • [ ] Pick up and start gabapentin (and possibly duloxetine).
  • [ ] Maintain high fluid intake; avoid NSAIDs.
  • [ ] Confirm date/time of 2-week follow-up with Dr. Hart.
  • [ ] Obtain lab requisition before appointment; complete labs 24–48 h prior.
  • [ ] Clarify bone-scan results and oncology transition status at UC Davis.